NASDAQ:MNOV

MediciNova Q3 2025 Earnings Results & Report

MediciNova logo
$1.28 -0.05 (-3.83%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MediciNova beat analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.06 versus the -$0.08 consensus estimate, while revenue was $123.32 thousand.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

MediciNova EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

MediciNova Revenue Results

Actual Revenue
$123.32 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

MediciNova Q3 2025 Earnings FAQ

MediciNova (NASDAQ:MNOV) reported earnings of -$0.06 per share for Q3 2025, beating the consensus estimate of -$0.08. The report was announced on Wednesday, November 12, 2025.

MediciNova reported revenue of $123.32 thousand for Q3 2025.

MediciNova Earnings Headlines

Medicinova Inc
MediciNova to Participate in the Maxim Growth Summit
Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries.

Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines.

MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.

View MediciNova Profile